BACKGROUND/AIM: We hypothesized that limited information is given to patients on the risks and benefits of individual therapy, and feedback is lacking to verify if patients correctly interpreted the given information. We assessed the perspectives of patients with inflammatory bowel disease (IBD) concerning the treatment-associated risks/benefits of infliximab. METHODS: Patients were asked to complete a survey regarding the benefits and risks of infliximab. Results are reported as descriptive statistics. Comparisons between groups were analyzed using independent t tests and the Kruskal-Wallis test. RESULTS: In total, 152 IBD patients completed the questionnaire. Fifty-seven percent (78/138) estimated the 1-year remission rate from infliximab to be >50%. Seventy-one percent (104/146) indicated they would not take a drug with risks reflecting those estimated for infliximab if the 1-year remission rate was <75%. Crohn's disease patients and those recalling a discussion regarding the risks/benefits of infliximab treatment had higher estimates of the 1-year remission rate with infliximab than ulcerative colitis patients (p = 0.03) and patients who did not recall previous information (p = 0.03). Perceptions were independent of age and disease duration. CONCLUSION: IBD patients misperceive the risks and benefits of infliximab. The majority of patients would not accept treatment-related risks if the 1-year remission rate was <75%. Counseling on treatment-associated risks and benefits should be ameliorated.
BACKGROUND/AIM: We hypothesized that limited information is given to patients on the risks and benefits of individual therapy, and feedback is lacking to verify if patients correctly interpreted the given information. We assessed the perspectives of patients with inflammatory bowel disease (IBD) concerning the treatment-associated risks/benefits of infliximab. METHODS:Patients were asked to complete a survey regarding the benefits and risks of infliximab. Results are reported as descriptive statistics. Comparisons between groups were analyzed using independent t tests and the Kruskal-Wallis test. RESULTS: In total, 152 IBDpatients completed the questionnaire. Fifty-seven percent (78/138) estimated the 1-year remission rate from infliximab to be >50%. Seventy-one percent (104/146) indicated they would not take a drug with risks reflecting those estimated for infliximab if the 1-year remission rate was <75%. Crohn's diseasepatients and those recalling a discussion regarding the risks/benefits of infliximab treatment had higher estimates of the 1-year remission rate with infliximab than ulcerative colitispatients (p = 0.03) and patients who did not recall previous information (p = 0.03). Perceptions were independent of age and disease duration. CONCLUSION:IBDpatients misperceive the risks and benefits of infliximab. The majority of patients would not accept treatment-related risks if the 1-year remission rate was <75%. Counseling on treatment-associated risks and benefits should be ameliorated.
Authors: Geert D'Haens; Filip Baert; Gert van Assche; Philip Caenepeel; Philippe Vergauwe; Hans Tuynman; Martine De Vos; Sander van Deventer; Larry Stitt; Allan Donner; Severine Vermeire; Frank J Van De Mierop; Jean-Charles R Coche; Janneke van der Woude; Thomas Ochsenkühn; Ad A van Bodegraven; Philippe P Van Hootegem; Guy L Lambrecht; Fazia Mana; Paul Rutgeerts; Brian G Feagan; Daniel Hommes Journal: Lancet Date: 2008-02-23 Impact factor: 79.321
Authors: Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel Journal: N Engl J Med Date: 2005-12-08 Impact factor: 91.245
Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts Journal: Lancet Date: 2002-05-04 Impact factor: 79.321
Authors: Corey A Siegel; Chin Hur; Joshua R Korzenik; G Scott Gazelle; Bruce E Sands Journal: Clin Gastroenterol Hepatol Date: 2006-07-14 Impact factor: 11.382
Authors: Marc Lémann; Jean-Yves Mary; Bernard Duclos; Michel Veyrac; Jean-Louis Dupas; Jean Charles Delchier; David Laharie; Jacques Moreau; Guillaume Cadiot; Laurence Picon; Arnaud Bourreille; Iradj Sobahni; Jean-Frederic Colombel Journal: Gastroenterology Date: 2006-04 Impact factor: 22.682
Authors: Jean-Frederic Colombel; Edward V Loftus; William J Tremaine; Laurence J Egan; W Scott Harmsen; Cathy D Schleck; Alan R Zinsmeister; William J Sandborn Journal: Gastroenterology Date: 2004-01 Impact factor: 22.682
Authors: Lorraine I Kelley-Quon; Howard C Jen; David A Ziring; Neera Gupta; Barbara S Kirschner; George D Ferry; Stanley A Cohen; Harland S Winter; Melvin B Heyman; Benjamin D Gold; Stephen B Shew Journal: J Pediatr Gastroenterol Nutr Date: 2012-11 Impact factor: 2.839
Authors: Corey A Siegel; Jennifer H Lofland; Ahmad Naim; Jan Gollins; Danielle M Walls; Laura E Rudder; Chuck Reynolds Journal: Patient Date: 2016-02 Impact factor: 3.883
Authors: Corey A Siegel; Jennifer H Lofland; Ahmad Naim; Jan Gollins; Danielle M Walls; Laura E Rudder; Chuck Reynolds Journal: Dig Dis Sci Date: 2015-05-05 Impact factor: 3.199
Authors: David T Rubin; Ailsa Hart; Remo Panaccione; Alessandro Armuzzi; Ulla Suvanto; J Jasper Deuring; John Woolcott; Joseph C Cappelleri; Kathy Steinberg; Laura Wingate; Stefan Schreiber Journal: Inflamm Bowel Dis Date: 2021-06-15 Impact factor: 5.325